What s New in Depression in 2016? By: Phyliss Nicole Taylor, MD UF Health Jacksonville Psychiatry
|
|
- Amanda Ethel King
- 6 years ago
- Views:
Transcription
1 What s New in Depression in 2016? By: Phyliss Nicole Taylor, MD UF Health Jacksonville Psychiatry
2 New Depression Screening Guidelines US Preventive Services Task Force (USPSTF) updated its 2009 recommendations [1] General adult population aged 18 years and older, including older adults Adding screening of pregnant and postpartum women (grade B= moderate level benefit) Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up PCP s to provide the screening for all patients, using effective screening tests such as the Patient Health Questionnaire, the Hospital Anxiety and Depression Scales in adults, the Geriatric Depression Scale in older adults, and the Edinburgh Postnatal Depression Scale in postpartum and pregnant women
3 Antidepressants in Pregnancy and Autism Use of SSRI s during the 2 nd or 3 rd trimester increases the risk of ASD in children, even after considering maternal depression [2] No increased risk for ASD was observed with the use of antidepressants during the first trimester 87% increase risk of having a child with autistic spectrum disorder, but absolute risk low The combined use of drugs from two or more antidepressant drug classes was associated with the highest risk of having a child with ASD Must weigh risks of exposure to SSRI vs. exposure to untreated depression for child
4 Rexulti (Brexpiprazole) Manufacturer: Otsuka FDA Approval Date: July 2015 Indications: For the adjunctive treatment of major depression and schizophrenia Recommended dosing (for depression): Start 0.5mg or 1 mg daily and titrate weekly to target dose of 2 mg daily; max =3 mg daily Most common side effects : akathisia (7-14%) and weight gain (<8%) MOA: atypical antipsychotic with combination of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors
5 Brintellix (Vortioxetine) Manufacturer: Takeda Pharmaceuticals USA FDA Approval Date: October 2013 Indications: For the treatment of Major Depressive Disorder; Improved cognitive function in major depression Recommended dosing: Start with 10 mg daily and can titrate up to 20 mg daily Most Common Side effects: nausea (21-32%), constipation, vomiting MOA: serotonin modulator and stimulator; inhibition of the reuptake of serotonin (5-HT); 5-HT3 receptor antagonism and 5-HT1A receptor agonism
6 Fetzima (Levomilnacipran) Manufacturer: Forest Laboratories FDA Approval Date: July 2013 Indication: For the treatment of major depressive disorder Recommended dosing: Start 20 mg daily x 2 days, then increase to 40 mg daily; titrate by 40 mg dose every 2 days until max= 120 mg daily MOA: extended release selective norepinephrine and serotonin reuptake inhibitor Enantiomer of Milnacipran (Savella)which is indicated for treatment of fibromyalgia
7 Role of Folate and Depression Borderline low or deficient serum or red blood cell folate levels have been detected in 15% to 38% of adults diagnosed with depressive disorders. [3] Low folate levels have been linked to poorer SSRI response Folate supplementation to antidepressants may lead to faster and more robust response and decreased relapses. Several brands of prescription folate on market: Enlyte, Deplin, Cerefolin
8 Ketamine and Depression Anesthetic or analgesic; illicitly used as hallucinogen MOA: Blocking the activity of glutamate on the N-methyl-D-aspartate (NMDA) receptor; also acts on opioid receptors and monoamine transporters Common side effects: psychological reactions as the medication wears off, elevated blood pressure and muscle tremors Rapid antidepressant effect in patients with treatment resistant unipolar and bipolar depression and people in suicidal crisis in ER[4] Given by a single IV infusion at doses less than those used in anesthesia, but may require multiple doses over a few days; intranasal spray also being studied Rapid response (within 1-2 hours) and relatively sustained (about 1 2 weeks long) reduction - in symptoms in some people
9 Opioids for Depression The short-term use of ultra-low-dose ( mg/day) sublingual buprenorphine for acute (<4 weeks), symptomatic, safe treatment for suicidal ideation [5] Useful adjunctive treatment to antidepressants, worked well in Borderline PD Most common side effects: fatigue, nausea, dry mouth, and constipation No withdrawal symptoms noted with abrupt discontinuation Caution in substance abusers MOA: Partial mu agonist and a potent kappa antagonist
10 Buprenorphine/Samidorphan (ALKS 5461) Phase III Clinical Trials for FDA approval for treatment resistant major depression in adjunct to SSRI or SNRI antidepressant [6] Manufacturer: Alkermes, Inc. Dosing: single SL tablet taken once daily MOA: Buprenorphine: partial mu agonist and a potent kappa antagonist; Samidorphan: a potent mu-opioid receptor antagonist (block the abuse and addiction of buprenorphine) Most common side effects: nausea, vomiting, and dizziness No indications of opioid withdrawal and no consistent signals of abuse liability associated with the treatment
11 Pharmacogenomic Testing Analyzes how patients genes may affect metabolism and response to certain antidepressants (and other medications) Genetic variations at CYP2D6 and CYP2C19 may affect serum levels of medications and predict more drug-drug interactions in people with comorbid medical conditions Polymorphisms in SLC6A4 (promoter region of the serotonin transporter gene) and 5-HT polymorphisms in serotonin receptors (2A and 2C subtypes) appear to influence SSRI response and side effects MTHFR tests provide information about folate deficiency which can affect depression and response to antidepressants Based on patients genetic status, physicians could predict their response to certain drugs, leading to better efficacy, fewer adverse drug reactions, and a better cost-benefit ratio FDA includes pharmacogenomics information in their labels DNA collected by buccal swab in office and sent for analysis, results to physician in 2-3 days Reimbursed by most insurances and Patient Assistance Plan is available.
12 Works Cited 1. Siu, Albert. Screening for Depression in Adults: US Preventive Services Task Force Recommendation Statement. Journal of American Medical Association (2016): Print. 2. Boukhris, Takoua et al. Antidepressant Use During Pregnancy and the Risk of Autism Spectrum Disorder in Children. Journal of American Medical Association Pediatrics (2016): Print. 3. Alpert, Jonathan et al. Nutrition and Depression: The Role of Folate. Medscape Psychiatry & Mental Health E Journal 2.1 (1997). Medscape. Web. 12 March Caddy C et al. Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database Systematic Reviews. (2015). Medscape. Web 12 March Yovell, Yoram et al. Ultra Low-Dose Buprenorphine as a Time-Limited Treatment for Severe Suicidal Ideation: A Randomized Controlled Trial. American Journal of Psychiatry (2015). Psychiatry Online. Web. 12 March Fava, Maurizio et al. Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double Blind Placebo Controlled Trial. American Journal of Psychiatry (2015). Psychiatry Online. Web. 12 March 2016
#CHAIR2016. September 15 17, 2016 The Biltmore Hotel Miami, FL. Sponsored by
#CHAIR2016 September 15 17, 2016 The Biltmore Hotel Miami, FL Sponsored by #CHAIR2016 Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders Alan F. Schatzberg,
More informationDepression Disease Market and Forecast Analysis 2024 Report Extract
Datamonitor Healthcare Pharma intelligence Depression Disease Market and Forecast Analysis 2024 Report Extract Find out more about the full report Contents (for full report) 10 FORECAST: DEPRESSION (Published
More informationObjectives. DSM-V Changes: Elimination of Multiaxial Diagnostic System
Conflicts of Interest I have no conflicts to disclose. 2014 Updates to the Updates in Pharmacotherapy Webinar Psychiatry Updates for Pharmacotherapy Specialists Jacintha S. Cauffield, Pharm.D., BCPS Associate
More informationAustedo. (deutetrabenazine) New Product Slideshow
Austedo (deutetrabenazine) New Product Slideshow Introduction Brand name: Austedo Generic name: Deutetrabenazine Pharmacological class: Vesicular monoamine transporter 2 (VMAT2) inhibitor Strength and
More informationLooking to the Horizon: Novel Agents in Development for the Treatment of Depression
Handout for the Neuroscience Education Institute (NEI) online activity: Looking to the Horizon: Novel Agents in Development for the Treatment of Depression Learning Objectives Explain the neurobiological
More informationMajor Depression and Anxiety in Adolescents and Adults
Major Depression and Anxiety in Adolescents and Adults Miggie Greenberg, M.D. Associate Professor of Psychiatry St. Louis University School of Medicine greenbml@slu.edu *NO DISCLOSURES* OBJECTIVES * Recognize
More informationObjectives. Objectives. A practice review. 02-Nov-16 MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS
MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS Jon-Paul Khoo What is treatment resistance really? Database review 328 consecutive non-remitted MDD patients referred for private
More informationAdvances in Diagnosis, Neurobiology, and Treatment of Mood Disorders
Advances in Diagnosis, Neurobiology, and Treatment of Mood Disorders June 13-14, 2016 Field House Coral Gables University of Miami Coral Gables, FL Advances in the Management of TreatmentResistant Depression
More informationPsychiatry curbside: Answers to a primary care doctor s top mental health questions
Psychiatry curbside: Answers to a primary care doctor s top mental health questions April 27, 2018 Laurel Ralston, DO Psychiatrist, Taussig Cancer Institute Objectives Review current diagnostic and prescribing
More informationDepression in Pregnancy
TREATING THE MOTHER PROTECTING THE UNBORN A MOTHERISK Educational Program The content of this program reflects the expression of a consensus on emerging clinical and scientific advances as of the date
More informationA Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression
REVIEW ARTICLE Drug Saf 2011; 34 (9): 709-731 0114-5916/11/0009-0709/$49.95/0 ª 2011 Adis Data Information BV. All rights reserved. A Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression
More informationDsuvia (sufentanil) NEW PRODUCT SLIDESHOW
Dsuvia (sufentanil) NEW PRODUCT SLIDESHOW Introduction Brand name: Dsuvia Generic name: Sufentanil Pharmacological class: Opioid agonist Strength and Formulation: 30mcg; sublingual tabs (housed in a disposable,
More informationDementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist
Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Medication Dosage Indication for Use Aricept (donepezil) Exelon (rivastigmine) 5mg 23mg* ODT 5mg Solution
More informationMood Disorders.
Mood Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationBeyond the antidepressant label: Neuroscience-based Nomenclature
Beyond the antidepressant label: Neuroscience-based Nomenclature Pierre Blier, MD, Ph.D Professor, Psychiatry and Cellular & Molecular Medicine University of Ottawa Endowed Chair and Director Mood Disorders
More informationProbuphine. (buprenorphine implant) New Product Slideshow
Probuphine (buprenorphine implant) New Product Slideshow Introduction Brand name: Probuphine Generic name: Buprenorphine Pharmacological class: Opioid (partial agonist-antagonist) Strength and Formulation:
More informationCurriculum Vitae, Michael J. Downing, M.D.
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com PROFESSIONAL AFFILIATIONS: Michael
More informationAntidepressant Selection in Primary Care
Antidepressant Selection in Primary Care Rebecca D. Lewis, DO OOA Summer CME Oklahoma City, OK 6 August 2017 Objectives Understand the epidemiology of depression. Recognize factors to help choose antidepressants.
More informationIV Ketamine Infusions for the Treatment of Depression: An Evidence Based Practice Analysis Sergio A. Quinones, SRNA Bryan College of Health Sciences
IV Ketamine Infusions for the Treatment of Depression: An Evidence Based Practice Analysis Sergio A. Quinones, SRNA Bryan College of Health Sciences Keywords: ketamine, depression, antidepressant, infusion,
More informationIf Not Opioids then LEAH EDMONDS CSHP OCTOBER 26, 2017
If Not Opioids then what LEAH EDMONDS CSHP OCTOBER 26, 2017 Disclosure Nothing to disclose Objectives Identify various non-opioid options for the treatment of chronic non cancer pain Choose appropriate
More informationDaniel Suzuki, MD Adjunct Clinical Associate Professor of Psychiatry, USC Keck School of Medicine Clinical Adjunct Professor/Faculty, Graduate School
Daniel Suzuki, MD Adjunct Clinical Associate Professor of Psychiatry, USC Keck School of Medicine Clinical Adjunct Professor/Faculty, Graduate School of Psychology, Fuller Theological Seminary Medical
More informationChief Operating Officer North Star Medical Research, LLC
CURRICULUM VITAE Joann M. Berenda, AAB Chief Operating Officer North Star Medical Research, LLC 18660 Bagley Road, Building II, Suite 205 Middleburg Heights, OH 44130 Telephone: Fax: email: +01 440 234
More information#CHAIR2015. Miami, Florida. September 24 26, JW Marriott Miami. Sponsored by
#CHAIR2015 September 24 26, 2015 JW Marriott Miami Miami, Florida Sponsored by New and Emerging Antidepressant Strategies in MDD Alan F. Schatzberg, MD Stanford University School of Medicine Stanford,
More informationWEIGHT LOSS/MANAGEMENT IS IT JUST ANOTHER PIPE DREAM?
WEIGHT LOSS/MANAGEMENT IS IT JUST ANOTHER PIPE DREAM? THE OBESITY MEDICINE ASSOCIATION S DEFINITION OF OBESITY Obesity is defined as a chronic, relapsing, multi-factorial, neurobehavioral disease, wherein
More informationQuick Guide to Common Antidepressants-Adults
Quick Guide to Common Antidepressants-Adults Medication Therapeutic Range (mg/day) Initial Suggested Serotonin Reuptake Inhibitors (SSRIs) All available as generic FLUOXETINE (Prozac) CITALOPRAM (Celexa
More informationESCITALOPRAM. THERAPEUTICS Brands Lexapro see index for additional brand names. Generic? Yes
ESCITALOPRAM THERAPEUTICS Brands Lexapro see index for additional brand names Generic? Yes Class SSRI (selective serotonin reuptake inhibitor); often classified as an antidepressant, but it is not just
More informationSwitching antipsychotics: Basing practice on pharmacology & pharmacokinetics
Switching antipsychotics: Basing practice on pharmacology & pharmacokinetics John Donoghue Liverpool L imagination est plus important que le savoir Albert Einstein Switching Antipsychotics: Objectives
More informationTIAGABINE. THERAPEUTICS Brands Gabitril see index for additional brand names. Generic? Yes
TIAGABINE THERAPEUTICS Brands Gabitril see index for additional brand names Generic? Yes Class Anticonvulsant; selective GABA reuptake inhibitor (SGRI) Commonly Prescribed for (bold for FDA approved) Partial
More informationPsychotropic Drugs in the Pipeline. Norman Sussman, M.D. Professor of Psychiatry New York University School of Medicine
Psychotropic Drugs in the Pipeline Norman Sussman, M.D. Professor of Psychiatry New York University School of Medicine Norman Sussman, MD No Conflict of Interest to Declare Antidepressant Pipeline We need
More informationWHAT S NEW. Vilazodone (Viibryd ) Vilazodone - Dosing ANTIDEPRESSANT UPDATE: What s New? The Cardiac Debate The Efficacy Debate?Pharmacogenomics?
ANTIDEPRESSANT UPDATE: What s New? The Cardiac Debate The Efficacy Debate?Pharmacogenomics? Rex S. Lott, Pharm.D., BCPP Professor, ISU College of Pharmacy Mental Health Clinical Pharmacist, Boise VAMC
More informationPractice Guideline for the Treatment of Patients With Major Depressive Disorder: American Psychiatric Association
Practice Guideline for the Treatment of Patients With Major Depressive Disorder: American Psychiatric Association Our clinical advisor adds updated advice on electroconvulsive therapy, transcranial magnetic
More informationCHAIR SUMMIT 7TH ANNUAL #CHAIR2014. Master Class for Neuroscience Professional Development. September 11 13, Westin Tampa Harbour Island
#CHAIR2014 7TH ANNUAL CHAIR SUMMIT Master Class for Neuroscience Professional Development September 11 13, 2014 Westin Tampa Harbour Island Sponsored by #CHAIR2014 Bipolar Depression: Putting the End Goal
More informationFAQ - ARIPIPRAZOLE Educational materials for the Healthcare profesionals
FAQ - ARIPIPRAZOLE Educational materials for the Healthcare profesionals Aripiprazole Dr. Reddy's 5, 10, 15 and 30 mg film-coated tablets Aripiprazole is indicated for the treatment up to 12 weeks of moderate-to-severe
More informationLemilvo Tablets (aripiprazole)
Lemilvo Tablets (aripiprazole) Healthcare Professional Frequently Asked Questions (FAQ) Brochure Bipolar I Disorder in Adolescents Lemilvo (aripiprazole) is indicated for the treatment up to 12 weeks of
More informationHMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in
HMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in Anesthesia and Neurology Harvard Medical School Limited time
More informationAntidepressant Therapy 2016
Antidepressant Therapy 2016 Michael E. Thase, MD University of Pennsylvania School of Medicine Philadelphia Veterans Affairs Medical Center University of Pittsburgh Medical Center thase@mail.med.upenn.edu
More informationOptimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE
Optimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE Chan-Hyung Kim, MD Severance Mental Health Hospital Institute of Behavioral Science in Medicine Diagnostic Criteria Pyramid Etiologic Pathophysiologic
More information3/27/2013. Objectives. Psychopharmacology at the End of Life Nicole Thurston, MD
Psychopharmacology at the End of Life Nicole Thurston, MD Psychiatrist Mountain States Tumor Institute Objectives Describe 2 common psychiatric symptoms that can present at or near end of life. Review
More informationAdult Depression - Clinical Practice Guideline
1 Adult Depression - Clinical Practice Guideline 05/2018 Diagnosis and Screening Diagnostic criteria o Please refer to Attachment A Screening o The United States Preventative Services Task Force (USPSTF)
More informationDepression Rising (Again): Turning the Corner in Psychiatry s Most Burdensome Disorder
Depression Rising (Again): Turning the Corner in Psychiatry s Most Burdensome Disorder Joel Sandler, Ph.D. Associate Principal, Defined Health Harry Tracy, Ph.D. Founder and President, NI Research Roger
More informationONCE-DAILY DOSING WITH NUPLAZID
YOUR GUIDE TO ONCE-DAILY DOSING WITH NUPLAZID NUPLAZID (pimavanserin) is the first and only FDAapproved treatment for hallucinations and delusions associated with Parkinson s disease psychosis 1 Indication
More informationWHAT S THE SKINNY ON WEIGHT LOSS MEDICATION SAFETY? January 25, 2019 Pennsylvania Pharmacists Association
WHAT S THE SKINNY ON WEIGHT LOSS MEDICATION SAFETY? January 25, 2019 Pennsylvania Pharmacists Association MEGAN N DUNLOP, PHARMD, CTTS CLINICAL PHARMACIST, UPMC COMMUNITY PROVIDER SERVICES LEARNING OBJECTIVES
More informationUpdate on Novel Agents in Resistant Depression
Update on Novel Agents in Resistant Depression Charles DeBa7sta, MD Professor of Psychiatry and Behavioral Sciences Stanford University School of Medicine Disclosures Research Support, Astra Zeneca, CNS
More informationDRUGS THAT ACT IN THE CNS
DRUGS THAT ACT IN THE CNS Anxiolytic and Hypnotic Drugs Dr Karamallah S. Mahmood PhD Clinical Pharmacology 1 OTHER ANXIOLYTIC AGENTS/ A. Antidepressants Many antidepressants are effective in the treatment
More informationDiagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD
Diagnosis & Management of Major Depression: A Review of What s Old and New Cerrone Cohen, MD Why You re Treating So Much Mental Health 59% of Psychiatrists Are Over the Age of 55 AAMC 2014 Physician specialty
More informationMORE THAN MONOAMINES: A LOOK AT NOVEL ANTIDEPRESSANTS
MORE THAN MONOAMINES: A LOOK AT NOVEL ANTIDEPRESSANTS Learning Objective Describe the molecular targets of novel agents, including adjunctive treatments, currently being investigated 50% of Patients Respond
More informationBUPROPION. THERAPEUTICS Brands Wellbutrin, Wellbutrin SR, Wellbutrin XL Zyban Aplenzin
BUPROPION THERAPEUTICS Brands Wellbutrin, Wellbutrin SR, Wellbutrin XL Zyban Aplenzin Generic? Yes Class Neuroscience-based Nomenclature: dopamine reuptake inhibitor and releaser (D-RIRe) NDRI (norepinephrine
More informationREBOXETINE. THERAPEUTICS Brands Norebox Edronax see index for additional brand names. Generic? No
REBOXETINE THERAPEUTICS Brands Norebox Edronax see index for additional brand names Generic? No Class Neuroscience-based Nomenclature: norepinephrine reuptake inhibitor (N-RI) Selective norepinephrine
More informationSuboxone, Zubsolv, Bunavail (buprenorphine with naloxone sublingual tablets and film), Buprenorphine sublingual tablets
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.32 Subject: Suboxone Drug Class Page: 1 of 7 Last Review Date: June 24, 2016 Suboxone Drug Class Description
More information10 INDEX Acknowledgements, i
INDEX 10 INDEX Acknowledgements, i Acute Care, Admissions to, 3.83 Discharge Planning, 3.86 Involuntary Admission Criteria, 3.84 List of Designated Provincial and Regional Mental Health Facilities, 3.83
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Trintellix) Reference Number: CP.PMN.65 Effective Date: 05.01.15 Last Review Date: 08.18 Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy
More informationNovel Treatments for Major Depression
Novel Treatments for Major Depression Dan V. Iosifescu, M.D., M.Sc. Associate Professor of Psychiatry and Neuroscience Icahn School of Medicine at Mount Sinai Consultant in Psychiatry, Massachusetts General
More information) and serotonin Type 2 (5-HT 2A
Latuda (lurasidone HCl) Fact Sheet Schizophrenia FREQUENTLY ASKED QUESTIONS What type of patient with schizophrenia is appropriate for LATUDA? LATUDA is an atypical antipsychotic agent indicated for the
More informationChildren s Hospital Of Wisconsin
Children s Hospital Of Wisconsin Co-Management Guidelines To support collaborative care, we have developed guidelines for our community providers to utilize when referring to, and managing patients with,
More informationThe Safety and Efficacy of Ondansetron in the Treatment of Obsessive Compulsive Disorder
Duquesne University Duquesne Scholarship Collection Graduate Student Research Symposium The 4th Annual Graduate Student Research Symposium September 19, 2017 The Safety and Efficacy of Ondansetron in the
More informationSP.236 / ESG.SP236 Exploring Pharmacology Spring 2009
MIT OpenCourseWare http://ocw.mit.edu SP.236 / ESG.SP236 Exploring Pharmacology Spring 2009 For information about citing these materials or our Terms of Use, visit: http://ocw.mit.edu/terms. Atypical (2
More informationPharmacogenetics in: Primary Care. Bradley T. Wajda D.O.
Pharmacogenetics in: Primary Care Bradley T. Wajda D.O. Pharmacogenomics Defined Pharmacogenomics uses information about a person s genetic makeup, or genome, to choose the drugs and drug doses that are
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Rexulti) Reference Number: CP.PMN.68 Effective Date: 11.05.15 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important Reminder
More informationAbilify (aripiprazole)
Abilify (aripiprazole) FDA ALERT [04/2005] Abilify is a type of medicine called an atypical antipsychotic. FDA has found that older patients treated with atypical antipsychotics for dementia had a higher
More informationWhat's New in the World of Antipsychotics?
Handout for the Neuroscience Education Institute (NEI) online activity: What's New in the World of Antipsychotics? (page 7 in syllabus) Stephen M. Stahl, MD, PhD Adjunct Professor, Department of Psychiatry
More informationPL CE LIVE February 2011 Forum
February 2011 PL CE LIVE Kristin W. Weitzel, Pharm.D., CDE, FAPhA Associate Editor and Director of Editorial Projects Pharmacist s Letter/Prescriber s Letter Atypical Antipsychotics Atypical Antipsychotics
More informationPiecing the Puzzle Together: Pharmacologic Approaches to Behavioral Management in Autism Spectrum Disorder
Piecing the Puzzle Together: Pharmacologic Approaches to Behavioral Management in Autism Spectrum Disorder Hannah Sauer, PharmD PGY1 Pediatric Pharmacy Resident Mayo Clinic 2015 MFMER slide-1 Objectives
More informationAnxiety Disorders.
Anxiety Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationOST. Pharmacology & Therapeutics. Leo O. Lanoie, MD, MPH, FCFP, CCSAM, ABAM, MRO
OST Pharmacology & Therapeutics Leo O. Lanoie, MD, MPH, FCFP, CCSAM, ABAM, MRO Disclaimer In the past two years I have received no payment for services from any agency other than government or academic.
More informationREXULTI (brexpiprazole) oral tablet
REXULTI (brexpiprazole) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationPediatric Psychopharmacology
Pediatric Psychopharmacology General issues to consider. Pharmacokinetic differences Availability of Clinical Data Psychiatric Disorders can be common in childhood. Early intervention may prevent disorders
More informationUpdate on Pain: Collaborative Care for the Complex Patient
Update on Pain: Collaborative Care for the Complex Patient Nirmala R. Abraham, MD Medical Director Sycamore Pain Management Center Kettering Health Network Objectives Standardized approach to patient care
More information^ PRIMER OF DRUG ACTION A comprehensive gyide to the actions, uses, and side effects of psychoactive drugs
^ PRIMER OF DRUG ACTION A comprehensive gyide to the actions, uses, and side effects of psychoactive drugs wm, ROBERT M.JULIEN M.D.. PH.D. Claire D. Advokat, Ph.D. Louisiana State University and Joseph
More informationPHARMACOTHERAPY OF SMOKING CESSATION
PHARMACOTHERAPY OF SMOKING CESSATION Domenic A. Ciraulo, MD Director of Alcohol Pharmacotherapy Research Center for Addiction Medicine Department of Psychiatry Massachusetts General Hospital Disclosure
More informationFacts About BELBUCA (buprenorphine) Buccal Film
Facts About BELBUCA (buprenorphine) Buccal Film Indication BELBUCA is a recent FDA-approved medication for the treatment of chronic pain severe enough to require daily, around-the-clock, long-term opioid
More informationDepartment of Psychiatry AG Stimulationsverfahren in der Psychiatrie. The Role of Ketamine in Treatment-Resistant Depression
Department of Psychiatry AG Stimulationsverfahren in der Psychiatrie The Role of Ketamine in Treatment-Resistant Depression Dr. Heiko Albrecht The Role of Ketamine in Treatment-Resistant Depression 2 Presentation
More informationClinical Policy Title: Ketamine for treatment-resistant depression
Clinical Policy Title: Ketamine for treatment-resistant depression Clinical Policy Number: 00.02.13 Effective Date: January 1, 2016 Initial Review Date: August 19, 2015 Most Recent Review Date: January
More informationTRANYLCYPROMINE. THERAPEUTICS Brands Parnate see index for additional brand names. Generic? Yes
TRANYLCYPROMINE THERAPEUTICS Brands Parnate see index for additional brand names Generic? Yes Class Monoamine oxidase inhibitor (MAOI) Commonly Prescribed for (bold for FDA approved) Major depressive episode
More informationSECTION 9 : MANAGEMENT OF MOVEMENT DISORDERS AND EXTRAPYRAMIDAL SIDE EFFECTS
SECTION 9 : MANAGEMENT OF MOVEMENT DISORDERS AND EXTRAPYRAMIDAL SIDE EFFECTS Formulary and Prescribing Guidelines 9.1 Introduction Movement disorders and extrapyramidal side effects can manifest in the
More informationPsychopharmacologic Updates. Nimisha Gokaldas, MD Medical Director Multnomah County, Mental Health and Addiction Services Division
Psychopharmacologic Updates Nimisha Gokaldas, MD Medical Director Multnomah County, Mental Health and Addiction Services Division This author has NO affiliations with or involvement in any organization
More informationSlide 1. Slide 2. Slide 3. Opioid (Narcotic) Analgesics and Antagonists. Lesson 6.1. Lesson 6.1. Opioid (Narcotic) Analgesics and Antagonists
Slide 1 Opioid (Narcotic) Analgesics and Antagonists Chapter 6 1 Slide 2 Lesson 6.1 Opioid (Narcotic) Analgesics and Antagonists 1. Explain the classification, mechanism of action, and pharmacokinetics
More informationWomen s Mental Health
Women s Mental Health Linda S. Mullen, MD Director, Women s Mental Health Assistant Professor of Clinical Psychiatry in OB/GYN Columbia University & NewYork Presbyterian Hospital Departments of Psychiatry
More information2013 Virtual AD/HD Conference 1
Medication for & Coexisting Conditions Part 2 Dr. Kenny Handelman Child, Adolescent & Adult Psychiatrist Halton Healthcare Adjunct Professor of Psychiatry, University of Western Ontario www.drkenny.com
More informationLURASIDONE. THERAPEUTICS Brands LATUDA see index for additional brand names
LURASIDONE THERAPEUTICS Brands LATUDA see index for additional brand names Generic? No Class Neuroscience-based Nomenclature: dopamine, serotonin receptor antagonist (DS-RAn) Atypical antipsychotic (serotonin-dopamine
More informationFact Sheet. Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII
Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII Fact Sheet Zohydro ER (hydrocodone bitartrate) Extended-Release Capsule, CII, is a long-acting (extendedrelease) type of pain medication
More informationAggression (Severe) in Children under Age 6
Aggression (Severe) in Children under Age 6 Level 0 Comprehensive diagnostic assessments. Refer to Principles of Practice on page 6. Evaluate and treat comorbid conditions (i.e. medical, other psychiatric
More informationNovel Treatments for Mood Disorders
Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts General Hospital Disclosures My spouse/partner and I
More informationThis initial discovery led to the creation of two classes of first generation antidepressants:
Antidepressants - TCAs, MAOIs, SSRIs & SNRIs First generation antidepressants TCAs and MAOIs The discovery of antidepressants could be described as a lucky accident. During the 1950s, while carrying out
More informationANTIDEPRESSANTS: SSRIs (p.7) 15. Dual-Action SSRIs (cont.)
ANTIDEPRESSANTS: SSRIs (p.7) 15. Dual-Action SSRIs (cont.) duloxetine (Cymbalta) has now passed clinical trials and can be prescribed (update to Julien, 10 th ) blocks reuptake of NE and 5HT (more complete
More informationSupernus Pharmaceuticals
Supernus Pharmaceuticals Investor Presentation March 2017 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 February 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 February 2009 ABILIFY 5 mg tablets, pack of 28 (CIP: 364 069-7) ABILIFY 10 mg tablets, pack of 28 (CIP: 364 073-4)
More informationPHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES
PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES Table of Contents Print TABLE OF CONTENTS Drug Page Number Anafranil... 2 Asendin... 4 Celexa... 4 Cymbalta... 6 Desyrel... 8 Effexor...10 Elavil...14
More informationREFERENCE CODE GDHC425DFR PUBLICAT ION DATE M AY 2014 BREXPIPRAZOLE (MAJOR DEPRESSIVE DISORDER) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC425DFR PUBLICAT ION DATE M AY 2014 BREXPIPRAZOLE (MAJOR DEPRESSIVE DISORDER) - Executive Summary Table below presents the key metrics for brexpiprazole in the Major Depressive Disorder
More informationFLUVOXAMINE. THERAPEUTICS Brands Luvox, Luvox CR see index for additional brand names. Generic? Yes (not for fluvoxamine CR)
FLUVOXAMINE THERAPEUTICS Brands Luvox, Luvox CR see index for additional brand names Generic? Yes (not for fluvoxamine CR) Class SSRI (selective serotonin reuptake inhibitor); often classified as an antidepressant,
More informationNuplazid. (pimavanserin) New Product Slideshow
Nuplazid (pimavanserin) New Product Slideshow Introduction Brand name: Nuplazid Generic name: Pimavanserin Pharmacological class: Atypical antipsychotic Strength and Formulation: 17mg; tablets Manufacturer:
More informationBupropion HCl, bupropion hydrobromide Wellbutrin SR, Wellbutrin XL, Zyban, Aplenzin, Forfivo XL
Bupropion Generic names Available brands Available strengths and formulations Available in generic Bupropion HCl, bupropion hydrobromide Wellbutrin SR, Wellbutrin XL, Zyban, Aplenzin, Forfivo XL 75-mg
More information(levomilnacipran) extended-release capsules
MEDICATION GUIDE FETZIMA (fet-zee-muh) (levomilnacipran) extended-release capsules Read this Medication Guide before you start taking FETZIMA and each time you get a refill. There may be new information.
More informationPharmacotherapy of psychosis and schizophrenia in youth
Pharmacotherapy of psychosis and schizophrenia in youth Benedetto Vitiello Pavia, 2 December 2017 Disclosure Benedetto Vitiello, M.D. Professor of Child and Adolescent Neuropsychiatry University of Turin,
More informationBRIEF ANTIDEPRESSANT OVERVIEW. Casey Gallimore, Pharm.D., M.S.
BRIEF ANTIDEPRESSANT OVERVIEW Casey Gallimore, Pharm.D., M.S. Antidepressant Medication Classes First Generation Tricyclic Antidepressants (TCAs) Monoamine Oxidase Inhibitors (MAOIs) Second Generation
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 1Q18 January February
BRAND NAME Austedo TM GENERIC NAME Deutetrabenazine MANUFACTURER Teva Pharmaceuticals USA, Inc. DATE OF APPROVAL August 30, 2017 PRODUCT LAUNCH DATE Currently commercially available REVIEW TYPE Review
More informationAnnex C. (variation to nationally authorised medicinal products)
Annex C (variation to nationally authorised medicinal products) Annex I Scientific conclusions and grounds for variation to the terms of the marketing authorisations Scientific conclusions Taking into
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE. Opinion. 1 October 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 1 October 2008 EFFEXOR SR 37.5 mg prolonged-release capsule B/30 (CIP: 346 563-3) EFFEXOR SR 75 mg prolonged-release
More informationREFERENCE CODE GDHC422DFR PUBLICAT ION DATE M AY 2014 BRINTELLIX (MAJOR DEPRESSIVE DISORDER) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC422DFR PUBLICAT ION DATE M AY 2014 BRINTELLIX (MAJOR DEPRESSIVE DISORDER) - Executive Summary Table below presents the key metrics for Brintellix in the seven major pharmaceutical markets
More informationPhentermine Hydrochloride
Weight Loss Medications Phentermine Hydrochloride Drug Enforcement Agency DEA: Schedule IV drug Indications: It is approved as monotherapy as a weight loss drug Doses To be taken once a day in the morning
More information